Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells

Molecular and Cellular Biochemistry

Volumn 357, Issue 1-2, 2011, Pages 31-38

  Li, Jian ^a,b   Zhang, Yangde ^a   Zhao, Jingfeng ^b   Kong, Fangren ^a   Chen, Yuxiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Chemoresistance; Colon cancer; MiRNA; Paclitaxel

Indexed keywords

CASPASE 3; MICRORNA 22; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN P53; ANTINEOPLASTIC AGENT; MICRORNA; MIRN22 MICRORNA, HUMAN; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; WILD TYPE; CELL STRAIN HCT116; CELL STRAIN HT29; COLON TUMOR; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HCT116 CELLS; HT29 CELLS; HUMANS; MICRORNAS; MUTATION; PACLITAXEL; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84870475369     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0872-8     Document Type: Article

References (33)

1. "Cancer". National Cancer Institute. (2009) http://www.cancer.gov/cancertopics
2. Xu AG, Yu ZJ, Jiang B, Wang XY, Zhong XH, Liu JH, Lou QY, Gan AH (2010) Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol 16:960-965
3. Ades S (2009) Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. Oncology 23:162-167
4. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584 (Pubitemid 47106628)
5. Dai A, Huang Y, Sadee W (2004) Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem 4: 1347-1356 (Pubitemid 39242877)
6. De Ligio JT, Velkova A, Zorio DA, Monteiro AN (2009) Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem 9:543-549
7. Shitara K, Oze I, Mizota A, Kondo C, Nomura M, Yokota T, Takahari D, Ura T, Yuki S, Komatsu Y, Matsuo K, Muro K (2010) Randomized phase II study comparing dose escalated weekly paclitaxel vs. standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer. Jpn J Clin Oncol [Epub ahead of print]
8. Hiro J, Inoue Y, Toiyama Y, Yoshiyama S, Tanaka K, Mohri Y, Miki C, Kusunoki M (2010) Possibility of paclitaxel as an alternative radiosensitizer to 5-fluorouracil for colon cancer. Oncol Rep 24:1029-1034
9. Skobeleva N, Menon S, Weber L, Golemis EA, Khazak V (2007) In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors. Mol Cancer Ther 6:898-906 (Pubitemid 46554559)
10. Haldar S, Jena N, Croce CM (1995) Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507-4511
11. Djeu JY, Wei S (2009) Clusterin and chemoresistance. Adv Cancer Res 105:77-92
12. Argov M, Bod T, Batra S, Margalit R (2010) Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein's cellular localization. Eur J Pharm Sci 41:53-59
13. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20:515-524 (Pubitemid 43345317)
14. Bagga S, Pasquinelli AE (2006) Identification and analysis of microRNAs. Genet Eng (NY) 27:1-20
15. Bar N, Dikstein R (2010) miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One 5:e10859
16. Xiong J, Du Q, Liang Z (2010) Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene 29:4980-4988
17. Ting Y, Medina DJ, Strair RK, Schaar DG (2010) Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression. Biochem Biophys Res Commun 394:606-611
18. Mi J, Zhang X, Rabbani ZN, Liu Y, Su A, Vujaskovic Z, Kontos CD, Sullenger BA, Clary BM (2006) H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to highlevel inhibition of intracellular protein activity. Nucleic Acids Res 34:3577-3584
19. Zhang X, Li Y, Huang Q, Wang H, Yan B, Dewhirst MW, Li CY (2003) Increased resistance of tumor cells to hyperthermia mediated by integrin-linked kinase. Clin Cancer Res 9:1155-1160 (Pubitemid 36323725)
20. McEwan DG, Brunton VG, Baillie GS, Leslie NR, Houslay MD, Frame MC (2007) Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res 67:5248-5257 (Pubitemid 46997263)
21. McDonald GT, Sullivan R, Paré GC, Graham CH (2010) Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Exp Cell Res 316:3197-3206
22. Huang WC, Hung MC (2009) Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 108:180-194
23. Li Z, Thiele CJ (2007) Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway. Expert Opin Ther Targets 11:1611-1621 (Pubitemid 350300963)
24. Zhang X, Mi J, Wetsel WC, Davidson C, Xiong X, Chen Q, Ellinwood EH, Lee TH (2006) PI3 kinase is involved in cocaine behavioral sensitization and its reversal with brain area specificity. Biochem Biophys Res Commun 340:1144-1150 (Pubitemid 43083398)
25. Sasabe E, Tatemoto Y, Li D, Yamamoto T, Osaki Y (2005) Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 96:394-402 (Pubitemid 41179740)
26. Blanco-Aparicio C, Renner Q, Leal JF, Carnero A (2007) PTEN, more than the AKT pathway. Carcinogenesis 28:1379-1386 (Pubitemid 47243536)
27. Yin Y, Shen WH (2008) PTEN a new guardian of the genome. Oncogene 27:5443-5453
28. Hu G, Wei Y, Kang Y (2009) The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res 15:5615-5620
29. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JT, Haffty BG, Kang Y (2009) MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15:9-20
30. Emdad L, Sarkar D, Su ZZ, Randolph A, Boukerche H, Valerie K, Fisher PB (2006) Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res 66:1509-1516 (Pubitemid 43259932)
31. Lee SG, Su ZZ, Emdad L, Sarkar D, Fisher PB (2006) Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc Natl Acad Sci USA 103:17390-17395 (Pubitemid 44788979)
32. Lee SG, Su ZZ, Emdad L, Sarkar D, Franke TF, Fisher PB (2008) Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 27:1114-1121 (Pubitemid 351253177)
33. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23:7518-7528 (Pubitemid 46291815)